Actively Recruiting
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
Led by University of California, San Francisco · Updated on 2025-01-08
23
Participants Needed
1
Research Sites
250 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
A
American Society of Clinical Oncology
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back after a period of improvement (recurrent). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Hypofractionated stereotactic radiosurgery may be safe, tolerable, and effective in treating patients with grade II or recurrent grade I meningiomas after surgical resection.
CONDITIONS
Official Title
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at time of study entry
- Ability to understand and willing to sign informed consent
- Histologic diagnosis of newly diagnosed WHO grade 2 or recurrent WHO grade 1 meningioma with radiographic evidence of recurrence
- Gross-total surgical resection of meningioma within 180 days before enrollment
- Pre-operative MRI available
- ECOG performance status of 0 or 1 (Karnofsky score 70 or higher)
- Post-operative MRI shows anatomy suitable for hypofractionated radiosurgery as reviewed by Radiation Oncology investigators
You will not qualify if you...
- Participation in another clinical study with an investigational product unless observational or follow-up only
- Extensive multifocal (3 or more) or metastatic meningiomas
- Tumors located within 2mm of optic apparatus or brainstem
- Active primary malignancy or history of malignancy except certain low-risk cancers unless in complete remission for 2+ years
- Pregnant female participants
- Medical or psychiatric conditions interfering with study evaluation
- Uncontrolled seizures with more than 3 disabling seizures per day on anti-epileptic drugs
- Previous intracranial radiotherapy overlapping the planned treatment area
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
J
Jamese Johnson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here